Navigation Links
VaxyGen Manufacturing Services LLC Announces Exclusive License and Collaborative Agreement with Georgia State University Research Foundation to Commercialize Novel Biological Process Development Patent, Expertise & Know-How
Date:10/19/2011

ATLANTA, Oct. 19, 2011 /PRNewswire/ -- VaxyGen Manufacturing Services LLC ("VaxyGen") announced today the signing of an exclusive license and collaboration agreement with Georgia State University Research Foundation ("GSURF") to provide VaxyGen the exclusive license to a novel patent for producing and purifying proteins in development as biopharmaceutical and vaccine products. In addition, VaxyGen and GSURF established a collaborative agreement whereby VaxyGen will commercialize the expertise and know-how resident in the Georgia State University Biological Process Development and Research Laboratory. Under the terms of the collaborative agreement, Professors George Pierce and Sid Crow will become Scientific/Technical Advisors to VaxyGen and Drs. Trudy Tucker and Shelby Jones will work with VaxyGen in the commercial development of the resident know-how and technology.

Commenting on the license and collaborative agreement, David Dodd, President/CEO, VaxyGen stated, "We have been most impressed with the expertise, know-how, technology and productivity resident within the GSU Biological Process Development and Research Laboratory. One of the greatest identified challenges in the development of life-enhancing biopharmaceutical and vaccine products is establishing consistent, successful optimization, purification and production of the underlying proteins related to development products. The GSU team has demonstrated their novel ability and consistent success in addressing and resolving these very challenging technical issues. We are confident that the biopharmaceutical and vaccine development marketplace will welcome and benefit from the broad commercialization of this technology and overall capability. In the end, patients will most benefit from the contributions resulting from this license and collaboration. We believe that this license and collaborative agreement are an excellent demonstration of improving life through affordable innovation."

Jim Weyhenmeyer, Ph.D., Chairman of GSURF and Vice President for Research and Economic Development at Georgia State University ("GSU"), added, "This agreement between GSURF and VaxyGen is a significant step in demonstrating the high-value translation of research at Georgia State University to improve human life through the successful development of biopharmaceutical and vaccine products. We are proud of the outstanding expertise and knowhow that has been developed at GSU's Biological Process Development and Research Laboratory and, we look forward to the successful contributions of that technology and expertise, ultimately to improve lives throughout the world. VaxyGen is an excellent partner to lead the successful translation of this expertise and know-how into the industry marketplace."

About VaxyGen Manufacturing Services LLC

VaxyGen Manufacturing Services LLC provides custom contract services in support of biological process optimization, scale-up and the development of manufacturing processes relative to biopharmaceutical and vaccine products. The Company is one of the operating businesses within VaxyGen Holdings LLC. VaxyGen Holdings LLC was established to provide vaccine products, assay services and manufacturing services, focused on improving life through affordable innovation.

About Georgia State University Research Foundation

The Georgia State University Research Foundation, Inc. (GSURF) is a Georgia nonprofit corporation created to support the research, technology commercialization and economic development activities of GSU. GSURF works to obtain research support funding through individuals, private organizations and public agencies. Grants awarded to the foundation are provided to the university, where scientists are given needed resources to conduct cutting edge research in a variety of fields, leading to new scientific understanding and technologies.

Contact:
Kathryn D. Gallagher
VaxyGen Manufacturing Services LLC
645 Meeting St.
Suite 2
Charleston, SC 29403
kgallagher@vaxygen.com
843/576-9840


'/>"/>
SOURCE VaxyGen Manufacturing Services LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
2. FDA Awards NIPTE Potential $35 Million in Grants to Reform Drug Manufacturing Process
3. Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021
4. Director of Commerce, Rogers Weed, Presided Over Ribbon Cutting Ceremony Celebrating Opening of Expanded Manufacturing Facility at CMC Biologics
5. Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets
6. Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets
7. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on North America
8. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on Europe
9. Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing
10. CMC Biologics Adds 2,000 Liter Single-Use Bioreactor at its Copenhagen Manufacturing Facility
11. Medical Device Manufacturing Conference Slated for October 19-20, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer market ... of the market globally. The stakeholders of this ... manufacture and commercialization of various mass spectrometer instrument ... to enter this market. This report comprises an ...
(Date:2/21/2017)... , Feb. 21, 2017  Luminex Corporation (NASDAQ: ... directors has authorized the initiation of a quarterly cash dividend ... initial cash dividend will be payable on April 14, 2017 ... on March 24, 2017. The board of ... cash dividend of $0.06 to holders of its common stock, ...
(Date:2/21/2017)... , Feb. 21, 2017  Global health services company ... Dermacell ® for breast reconstruction surgery and ... is an advanced acellular dermal matrix developed by LifeNet ... NVDQ ) "We are ... commercial health-care payers to review the growing base of ...
Breaking Medicine Technology:
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... coffee house-caliber protein espresso drinks, announced its products are now available for purchase ... Coffee Protein Drink Mix has become popular among health-conscious consumers who love coffee ...
(Date:2/20/2017)... ... February 21, 2017 , ... Nancy Johnston Toll ... a way to “ Getting Over the Bump in the Road ” (published by ... learned on how to cope with the ups and downs experienced by anyone going ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... Director, beth[at]orbitahealth[dot]com, +1 (414) 213-8818 , Orbita, Inc., a leading provider of innovative ... software-as-a-service solution for increasing patient engagement and optimizing care journey management for home ...
(Date:2/20/2017)... ... 20, 2017 , ... Today, Biscom , the leader ... first IoT device from Biscom designed to deliver confidential patient information securely and ... HIMSS17 and will be conducting demonstrations at Booth #374. , ...
(Date:2/20/2017)... Houston, TX (PRWEB) , ... February 20, 2017 ... ... he is now offering a full range of emergency dental care at his ... teeth and gums. When patients experience dental emergencies, they are at risk for ...
Breaking Medicine News(10 mins):